Literature DB >> 8632528

Intraoperative evaluation of renal cell carcinoma: a prospective study of the role of ultrasonography and histopathological frozen sections.

S C Campbell1, J Fichtner, A C Novick, F Steinbach, M Stöckle, E A Klein, D Filipas, H S Levin, S Störkel, F Schweden, N A Obuchowski, J Hale.   

Abstract

PURPOSE: Nephron sparing surgery is being performed increasingly for treatment of renal cell carcinoma, including in select patients with a normal contralateral kidney. The number of tumors in the involved kidney (single versus multiple) and presence or absence of perinephric fat involvement (pathological stage T1 to 2 versus T3A) are important prognostic factors. In a prospective study we evaluated the accuracy of intraoperative histopathological frozen section analysis of renal capsular biopsies for assessing local tumor stage, and the accuracy of intraoperative ultrasonography for assessing tumor focality.
MATERIALS AND METHODS: Intraoperative frozen section biopsies and ultrasonography were compared with information obtained from preoperative computerized tomography (CT), intraoperative inspection of the kidney by the surgeon and permanent histopathological specimens.
RESULTS: We evaluated 99 patients (102 kidneys) with localized sold renal masses undergoing either radical nephrectomy (48) or nephron sparing surgery (54). Final pathological analysis revealed 95 renal cell carcinomas (stage T3A in 24), 6 oncocytomas and 1 angiomyolipoma. Multiple tumors were detected in 18 of 102 kidneys overall. Frozen section analysis identified 87% of the stage T3A lesions with no false-positive results, compared to CT, which only identified 67%. Ultrasonography identified 14 of 18 multifocal tumors (78%) and was not more accurate than the combination of CT and intraoperative inspection. However, during nephron sparing surgery ultrasonography was useful to localize the intrarenal extent of tumors (17 cases).
CONCLUSIONS: Our results clarify the role of intraoperative ultrasonography and frozen section analysis in patients undergoing nephron sparing surgery for renal cell carcinoma. Frozen section analysis may be useful in select patients with small peripheral tumors who are under consideration for elective nephron sparing surgery.

Entities:  

Mesh:

Year:  1996        PMID: 8632528     DOI: 10.1016/s0022-5347(01)66211-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Evaluation of organ sparing operation results from planned indications in patients with kidney cancer.

Authors:  M Fryczkowski; A Potyka; J Huk
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Contrast enhanced ultrasound of renal masses.

Authors:  Andre Ignee; Bernd Straub; Gudrun Schuessler; Christoph Frank Dietrich
Journal:  World J Radiol       Date:  2010-01-28

Review 3.  Preoperative imaging in renal cell cancer.

Authors:  Axel Heidenreich; Vincent Ravery
Journal:  World J Urol       Date:  2004-07-30       Impact factor: 4.226

Review 4.  A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma.

Authors:  Ali Morshid; Elif S Duran; Woongsoon J Choi; Cihan Duran
Journal:  Cureus       Date:  2021-02-08

Review 5.  Open partial nephrectomy for the treatment of renal cell carcinoma.

Authors:  Brian Shuch; John S Lam; Arie S Belldegrun
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

6.  Laparoscopic wedge resection and partial nephrectomy--the Washington University experience and review of the literature.

Authors:  E M McDougall; A M Elbahnasy; R V Clayman
Journal:  JSLS       Date:  1998 Jan-Mar       Impact factor: 2.172

Review 7.  Imaging in genitourinary cancer from the urologists' perspective.

Authors:  P Tsakiris; J de la Rosette
Journal:  Cancer Imaging       Date:  2007-05-28       Impact factor: 3.909

8.  Importance and limits of ischemia in renal partial surgery: experimental and clinical research.

Authors:  Fernando P Secin
Journal:  Adv Urol       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.